Since 1997, Oxford University Innovation has been responsible for creating spinout companies based on academic research generated within and owned by the University of Oxford, and has spun out a new company every two months on average.
Over £266 million in external investment has been raised by Oxford University Innovation spinouts since 2000, and five are currently listed on London’s AIM market.
The creation of new spinout companies, most of which are listed below, also channels millions of pounds back into University research, benefits local economic development and has created many new jobs in the region.
At OxSyBio, we are developing 3D printing techniques to produce a range of tissue-like and functional tissues for medical research and clinical applications. Our vision is to ultimately produce tissues that can be used in the clinic for organ repair or replacement.
Professor Bayley’s group have previously demonstrated the ability to print three-dimensional networks comprising tens of thousands of picoliter aqueous droplets forming a cohesive material. These networks can be built in software-controlled geometries using a number of different droplet types, thus enabling them to perform simple cell-like functions and act as ‘tissue-like’ materials. Initial work showed that printed networks were capable of conducting electrical signals along neuron-like pathways by the selective incorporation of membrane proteins, or to fold in a pre-defined manner to assume altered shapes after printing.
OxSyBio is refining and advancing this technology to print more complex networks more rapidly and at a higher resolution. We are also adapting the approach to print living cells inside droplets, which will enable the direct printing of 3D cell networks with many of the characteristics of living tissues.
Incorporated in April 2014
Origin: Oxford University, Department of Chemistry
Develop cutting edge software applications that uncover the relationships between genetic variation and human disease.
Help pharmaceutical companies de-risk the drug development process.
Incorporated in March 2014
Origin: Oxford University, Wellcome Trust Centre for Human Genetics
Developing solutions for major unmet needs in diagnostic medicine in multiple internal organs. In the first instance the focus will be on, the detection and the accurate, quantitative measurement of liver, gallbladder and pancreatic disease, including precancerous and cancerous states in these organs.
Incorporated in April 2013
Origin: Oxford University, Department of Cardiovascular Medicine
Oxford Flow’s industrial pressure regulators use innovative technology to provide new levels of performance for natural gas transmission, water distribution and process industries.
Incorporated in September 2015
Origin: Oxford University, Department of Engineering Science
Developing a novel cancer immunotherapy discovered through a collaboration between Ludwig Cancer Research and Professor Vincenzo Cerundolo, the director of the MRC Human Immunology Unit within the University of Oxford’s Weatherall Institute of Molecular Medicine.
Origin: Oxford University, Radcliffe Department of Medicine
AnDy marries fine-engineering skills with a deep understanding of the fundamental mechanisms, to produce revolutionary machines that will change the shape of the future, taking inspiration from our environment in order to protect it, and capable of performance beyond anything currently found in nature or engineering.
Incorporated in April 2015
Origin: Oxford University, Department of Zoology